title: Injection site reactions after subcutaneous oligonucleotide therapy.
abstract: Oligonucleotides (ONs) are short fragments of nucleic acids, currently being investigated as therapeutic agents. When administered subcutaneously (sc), ONs cause a specific local reaction originating around the injection site, such as erythema, itching, discomfort and pain, including more severe manifestations such as ulceration or necrosis. These injection site reactions (ISRs) are common, but rather poorly described in the literature. With this review, we aim to provide an overview on the extent of the problem of ISRs, based on reported incidence. A structured literature search was performed to identify reported incidence and clinical features of ISRs which yielded 70 manuscripts that contained information regarding ISRs. The data from literature was combined with data on file available at our institution. All sc administered ONs described in the literature lead to the occurrence of ISRs. The percentage of trial subjects that developed ISRs ranged from 22 to 100% depending on ON. The majority of ONs caused ISRs in more than 70% of the trial subjects. The severity of the observed reactions varied between different ONs. Occurrence rate as well as severity of ISRs increases with higher doses. For chemistry and target of the compounds, no clear association regarding ISR incidence or severity was identified. All ONs developed to date are associated with ISRs. Overcoming the problem of ISRs might add greatly to the potential success of sc-administered ONs. Knowledge of these skin reactions and their specific immunostimulatory properties should be increased in order to obtain ONs that are more suitable for long-term use and clinically applicable in a broader patient population.
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Leonie
authors.initials: L
authors.lastname: van Meer
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Matthijs
authors.initials: M
authors.lastname: Moerland
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Jolie
authors.initials: J
authors.lastname: Gallagher
authors.affiliation: Department of Dermatology Erasmus MC, University Medical Center Rotterdam.
authors.forename: Martijn B A
authors.initials: MB
authors.lastname: van Doorn
authors.affiliation: Department of Dermatology Erasmus MC, University Medical Center Rotterdam.
authors.forename: Errol P
authors.initials: EP
authors.lastname: Prens
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Adam F
authors.initials: AF
authors.lastname: Cohen
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Robert
authors.initials: R
authors.lastname: Rissmann
authors.affiliation: Centre for Human Drug Research, Leiden, the Netherlands.
authors.forename: Jacobus
authors.initials: J
authors.lastname: Burggraaf
mesh_terms: D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D015994:Incidence; D007279:Injections, Subcutaneous; D009841:Oligonucleotides / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D009841:Oligonucleotides
keywords: antisense; injection site reaction; oligonucleotide; subcutaneous